HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $44
TD Cowen Initiates Coverage On Surrozen with Buy Rating
HC Wainwright & Co. Reiterates Buy on Surrozen, Raises Price Target to $36
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Surrozen Files Prospectus To Offer Up To $200M Of Securities
Surrozen Q4 EPS $(20.13) Misses $(1.08) Estimate, Sales $500.000K Inline
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cantor Fitzgerald Initiates Coverage On Surrozen with Overweight Rating, Announces Price Target of $40
Surrozen Conference: CEO Details Wnt-Fzd4 Eye Disease Bet, 2026 IND Plans for SZN-8141
We're Hopeful That Surrozen (NASDAQ:SRZN) Will Use Its Cash Wisely
Surrozen to Present at Upcoming Healthcare Investor Conferences
Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update
Surrozen Appoints Andrew Maleki CFO, Effective Nov. 12, Succeeding Charles Williams
Surrozen Q3 EPS $(8.36) Misses $(1.14) Estimate, Sales $983.000K Down From $10.000M YoY
Surrozen Announces Termination Of Collaboration Agreement With TCGFB, Effective November 13, 2025; No Side To Incur Any Termination Penalties
Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.